The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMedium•29 April 2026•

1 min read

Alector Discontinues Phase 2 Alzheimer's Trial Following Futility Analysis

Key Facts

1Alector confirmed the discontinuation of the Phase 2 PROGRESS-AD trial for nivisnebart after an independent data monitoring committee determined it was unlikely to meet its primary endpoint.

Alector, Inc. has announced the discontinuation of its Phase 2 PROGRESS-AD clinical trial for nivisnebart (AL101/GSK4527226), a candidate targeting early Alzheimer's disease. The decision follows an interim futility analysis conducted by an Independent Data Monitoring Committee (IDMC), which determined the trial was unlikely to meet its primary efficacy endpoints. In collaboration with its partner GSK, the company opted to terminate the study to optimize resource allocation across its broader pipeline. This clinical failure represents a significant setback for Alector's neurodegeneration portfolio and is expected to weigh heavily on investor sentiment. Biotech analysts anticipate downward pressure on the stock as the market recalibrates the value of the company's remaining assets. Alector remains focused on evaluating other clinical data to refine its strategic direction in the biotechnology sector.